1. Home
  2. MFM vs BNR Comparison

MFM vs BNR Comparison

Compare MFM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

MFM

MFS Municipal Income Trust

HOLD

Current Price

$5.47

Market Cap

223.2M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$31.01

Market Cap

216.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFM
BNR
Founded
1986
2014
Country
United States
China
Employees
N/A
N/A
Industry
Finance Companies
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.2M
216.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MFM
BNR
Price
$5.47
$31.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
108.1K
38.7K
Earning Date
01-01-0001
11-20-2025
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
N/A
$75,749,382.00
Revenue This Year
N/A
$136.32
Revenue Next Year
N/A
N/A
P/E Ratio
$176.67
N/A
Revenue Growth
N/A
5.56
52 Week Low
$4.37
$2.18
52 Week High
$5.48
$34.79

Technical Indicators

Market Signals
Indicator
MFM
BNR
Relative Strength Index (RSI) 57.30 70.59
Support Level $5.35 $19.10
Resistance Level $5.43 $34.79
Average True Range (ATR) 0.04 2.68
MACD 0.01 1.00
Stochastic Oscillator 68.42 81.96

Price Performance

Historical Comparison
MFM
BNR

About MFM MFS Municipal Income Trust

MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: